# A Comparison of SYMBICORT® pMDI With Budesonide HFA pMDI in African American Subjects With Asthma.

> **NCT00419952** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 742 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Budesonide/formoterol (SYMBICORT) pMDI
- **DRUG:** Budesonide HFA pMDI

## Key facts

- **NCT ID:** NCT00419952
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-02
- **Primary completion:** 2009-11
- **Final completion:** 2009-11
- **Target enrollment:** 742 (ACTUAL)
- **Last updated:** 2012-10-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00419952

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00419952, "A Comparison of SYMBICORT® pMDI With Budesonide HFA pMDI in African American Subjects With Asthma.". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00419952. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*